Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **polysaccharide capsule of Haemophilus influenzae type b** is a surface polymer composed of repeating units of **polyribosyl ribitol phosphate (PRP)**, forming a thick, hydrophilic layer that envelops the bacterium[4][6][8]. This capsule is the predominant **virulence determinant** of Hib, providing **resistance to host immune mechanisms**—particularly **complement-mediated killing and phagocytosis**—by masking surface antigens and preventing immune recognition[1][4][6]. The capsule’s structure is a linear polymer with (→3)-β-D-Ribofuranosyl-(1→1)-D-ribitol-5-phosphate repeating units[9]. Genes involved in its biosynthesis are organized in a dedicated genetic locus with both polymerization and export machinery, and its presence is essential for invasiveness in humans[1][2]. The capsule is the target of **licensed Hib conjugate vaccines**, which couple size-reduced or native PRP to carrier proteins (such as tetanus toxoid) to elicit a T-dependent immune response and induce high-affinity, protective anti-capsular antibodies[7][9]. These antibodies neutralize the pathogen by promoting phagocytosis and complement fixation, and their serum levels serve as **biomarkers for vaccine-induced protection**[8]. The minimal immunogenic epitope consists of two repeating units of PRP, providing the basis for next-generation synthetic or enzymatic vaccine design[3][5][7]. The capsule is not a therapeutic target for small-molecule drugs; its main relevance is as a **vaccine antigen** and marker of infection. Safety concerns related to targeting the capsule are minimal and limited mainly to vaccine formulation components, not the capsule itself.
Elicitation of protective anti-PRP antibody response (via conjugate vaccines) Neutralization/opsonization by antibodies targeting the capsule, leading to bacterial clearance Prevents colonization and invasive infection
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polysaccharide capsule of Haemophilus influenzae type b (PRP capsule (for "polyribosyl ribitol phosphate" capsule)).